RecruitingChronic Lymphocytic Leukemia
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Eligible age
18+ yrs
Accepts
All genders
Locations
5 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic lymphocytic leukemia (CLL).
Sponsor: BeOne Medicines
You may qualify if…
- ✓ Treatment-naïve (TN) adults with confirmed diagnosis of CLL which requires treatment
- ✓ Eastern Cooperative Oncology Group (ECOG) score 0, 1, or 2
- ✓ Measurable disease by Computer Tomography/Magnetic Resonance Imaging
- ✓ Adequate bone marrow and organ function
You may not qualify if…
- ✕ Previous systemic treatment for CLL
- ✕ Known prolymphocytic leukemia or history of, or currently suspected, Richter's transformation
- ✕ Known central nervous system involvement
- ✕ History of confirmed progressive multifocal leukoencephalopathy (PML)
- ✕ Uncontrolled hypertension or clinically significant cardiovascular disease
- ✕ Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Where it's recruiting
California
Duarte · Palo Alto
Illinois
Chicago · Zion
Louisiana
New Orleans
Nebraska
Omaha
Washington
Seattle
Source: ClinicalTrials.gov · NCT07277231 · last updated 2026-08-06